FDA approves automated insulin delivery and monitoring system for use in children aged 2 to 6 with type 1 diabetes

Approval is for MiniMed 770G System, first-of-a-kind device for this age group, comprising a hybrid closed loop diabetes management device intended to automatically monitor glucose and provide appropriate basal insulin doses with little or no input from users or their caregivers.


US Food and Drug Administration